Harnessing human genetics to develop next-generation biologics for patients with rare vascular diseases
About Us
Our team of scientists and clinicians combines deep domain expertise in vascular biology, with a strong track record in drug discovery and development.
Will Haining
CEO, Co-Founder
Nick Morrell, M.D.
CSO, Co-Founder
David Hoffmann
SVP Discovery, Co-Founder
David Grainger
Co-Founder
Nick Morrell M.D.
CSO & Co-Founder
- Emeritus Professor of Medicine, University of Cambridge
- Former CEO of Morphogen-IX (acquired by Centessa Pharmaceuticals, 2021)
- Previously Director of Cambridge Heart and Lung Research Institute
- Lifetime Achievement Award from European Respiratory Society for research in PAH
info@interact-bio.com
Will Haining Ph.D
CEO & Co-founder
- Previously Director of Strategic Innovations, Centessa Pharmaceuticals
- Biotech investment experience at MXC Capital and The Foundation Institute for 21st Century Medicine
- Ph.D. from Imperial College London, focussed on mechanically-regulated cell signalling pathways
info@interact-bio.com
David Hoffmann Ph.D
SVP Discovery, Co-Founder
- Previously Senior Manager of Strategic Innovations, Centessa Pharmaceuticals
- Former CSO & Co-Founder, Angios Bio
- Ph.D. from the Institute of Molecular Biotechnology Vienna (Joseph Pennginger’s lab), focussed on tumour angiogenesis and glycosylation biology
info@interact-bio.com
David Grainger Ph.D.
Co-Founder
- Venture Partner & Co-Founder, Medicxi
- Former Chief Innovation Officer at Centessa and is Co-Founder of The Foundation Institute for 21st Century Medicine
- Investments include: Padlock Therapeutics (acquired by Bristol-Myers Squibb), XO1 (acquired by Janssen Pharmaceuticals), Z-Factor (acquired by Centessa) and Morphogen-IX (acquired by Centessa)
- MA and Ph.D. degrees in Natural Sciences from the University of Cambridge, where he led an internationally-recognised research group in Cambridge University’s Department of Medicine
info@interact-bio.com
Our Investors
Harnessing the Power of Antibody Discovery and Engineering
The Dorothy Hodgkin Building,
Babraham Research Campus,
Cambridge, England CB22 3FH